We are live on ! Find out more
MDGSW

Medigus Series C Warrant

Delisted

MDGSW was delisted on the 19th of July, 2023.

0 hedge funds and large institutions have $0 invested in Medigus Series C Warrant in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 5 → 0 (-5)

100% less capital inflows, than outflows

Capital inflows: $0 | Capital outflows: $10.3K

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 5

Holders
–
Holders Change
-5
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

MDGSW Hedge Fund Activity: Q3 2023 in Review

0 of the 6,318 institutional investors tracked by Wall St. Rank reported a position in Medigus Series C Warrant (MDGSW) for Q3 2023, worth a combined $0 — down 100% from $10.3K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of MDGSW and 0 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Armistice Capital, exiting entirely with an estimated $5.06K sold.

  • 0 institutional investors held Medigus Series C Warrant (MDGSW) as of Q3 2023, down from 5 in Q2 2023.
  • Funds reported $0 of Medigus Series C Warrant stock for Q3 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Medigus Series C Warrant positions in Q3 2023 and 5 closed out, a net change of -5 holders.
  • The largest Medigus Series C Warrant seller in Q3 2023 was Armistice Capital, an estimated $5.06K sold.

Based on aggregated 13F filings for Q3 2023.